Top section
Top section
Streamlining of IPO process just two months after consultation closed as the market prepares for post-summer IPO activity
Sale comes after the expiry last month of a pre-emptive acquisition rights agreement between the main family holding companies
Placing and open offer follows recent acquisition of US annuity provider
More articles
More articles
More articles
-
China’s Simcere Pharmaceutical Group is seeking the green light to float on Hong Kong’s stock exchange after filing a listing application with the bourse. -
European investors are looking beyond the coronavirus crisis to put equity capital into companies that they believe can take advantage of its aftermath. However, as economies reopen after lockdown, the damage of the pandemic is becoming clearer, and companies are working hard to convince investors that they are the right horse to back.
-
BNP Paribas has provided €40bn of loans to corporate clients in the eye of the Covid-19 storm, amid claims that rivals are retrenching. David Rothnie asks if balance sheet support will result in bigger corporate finance fees.
-
Bonds of Unilever, the consumer goods firm, jumped on Thursday, despite it being a day of risk aversion in the markets, after it announced plans to merge its Dutch and UK entities. Unilever billed the move as simplifying its corporate structure to prepare for what it expects to be "the increasingly dynamic business environment that the Covid-19 pandemic will create" — as bankers predict industrial shake-ups will lead to mergers and acquisitions.
-
Hong Kong’s IPO market is gearing up for a busy few weeks as companies push for listing approvals before the end of June, with bankers and investors remaining bullish on the city’s stocks. Jonathan Breen reports.
-
Jiangxiaobai is planning to list in Hong Kong this year, according to a source close to the deal.
Sub-sections
shared comment list
